Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer

Eun Hye Kim; Hyuk Lee; Hyunsoo Chung; Jun Chul Park; Sung Kwan Shin; Sang Kil Lee; Woo Jin Hyung; Yong Chan Lee; Sung Hoon Noh

doi:10.1016/j.clinre.2013.11.009

Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer

Eun Hye Kim, Hyuk Lee, Hyunsoo Chung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Woo Jin Hyung, Yong Chan Lee, Sung Hoon Noh

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3%) and 21 (14.6%) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95% CI=5.3 to 59.4) and presence of MS (HR=2.8, 95% CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.

Original language	English
Pages (from-to)	372-378
Number of pages	7
Journal	Clinics and Research in Hepatology and Gastroenterology
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/j.clinre.2013.11.009
Publication status	Published - 2014 Jun

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clinre.2013.11.009

Cite this

@article{5ef8aadee5e246eb8fb8d83fb05fe405,

title = "Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer",

abstract = "Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3%) and 21 (14.6%) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95% CI=5.3 to 59.4) and presence of MS (HR=2.8, 95% CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.",

author = "Kim, {Eun Hye} and Hyuk Lee and Hyunsoo Chung and Park, {Jun Chul} and Shin, {Sung Kwan} and Lee, {Sang Kil} and Hyung, {Woo Jin} and Lee, {Yong Chan} and Noh, {Sung Hoon}",

year = "2014",

month = jun,

doi = "10.1016/j.clinre.2013.11.009",

language = "English",

volume = "38",

pages = "372--378",

journal = "Clinics and Research in Hepatology and Gastroenterology",

issn = "2210-7401",

publisher = "Elsevier Masson",

number = "3",

}

TY - JOUR

T1 - Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer

AU - Kim, Eun Hye

AU - Lee, Hyuk

AU - Chung, Hyunsoo

AU - Park, Jun Chul

AU - Shin, Sung Kwan

AU - Lee, Sang Kil

AU - Hyung, Woo Jin

AU - Lee, Yong Chan

AU - Noh, Sung Hoon

PY - 2014/6

Y1 - 2014/6

N2 - Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3%) and 21 (14.6%) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95% CI=5.3 to 59.4) and presence of MS (HR=2.8, 95% CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.

AB - Background: Few studies have reported the relationship between MS and the prognosis of gastric cancer. Methods: Data were collected from 505 patients who underwent radical gastrectomy for gastric cancer between January 2006 and December 2007. After exclusion, remaining 204 patients were divided into two groups based on the presence of MS. Results: No significant differences were observed in tumor stage and grade between the MS (n=60) and non-MS (n=144) groups. The median follow-up periods were 53.2. ±. 23.5 and 54.7. ±. 22.1 months in for the MS and non-MS groups, respectively (P=0.677). Seventeen (28.3%) and 21 (14.6%) patients showed tumor recurrence in the MS and non-MS groups, respectively (P=0.022). In addition, disease-free survival of patients in the MS group was less than in non-MS group (P=0.036). The Cox regression hazard model demonstrated that advanced tumor stage (stage III or IV, HR=17.8, 95% CI=5.3 to 59.4) and presence of MS (HR=2.8, 95% CI=1.3 to 5.8) were independent risk factors for recurrence. Conclusion: MS may be an important prognostic factor for gastric cancer. Control of MS could improve the therapeutic efficacy of gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84902505818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902505818&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2013.11.009

DO - 10.1016/j.clinre.2013.11.009

M3 - Article

C2 - 24485596

AN - SCOPUS:84902505818

SN - 2210-7401

VL - 38

SP - 372

EP - 378

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

IS - 3

ER -

Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this